Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc.

OOTC:KBLB
0.08
USD
+0.00
(-0.52%)
0.00EPS
113.40MMarket Cap
Kraig Biocraft Laboratories, Inc.
OTC:KBLB
(OTC Markets)

Recent

price

0.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
-0.01
- -
- -
- -
- -
- -
- -
-0.01
-0.01
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
Book Value per Share
- -
- -
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
Tangible Book Value per Share
402
573
596
616
662
686
744
791
817
836
849
878
974
1,033
1,038
1,059
1,088
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-9,246.04
-2,215.41
-239.02
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-1
-2
-7
-2
-2
-3
-2
-1
-3
-5
-8
-4
-3
-3
-4
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-9,648.57
-2,397.4
-291.07
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1
-1
-1
-1
-1
-2
-2
-3
-5
-5
-7
-6
-4
-6
-9
-9
-7
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
LT Debt
-1
-1
-1
-1
-1
-2
-2
-3
-4
-5
-7
-5
-4
-6
-8
-8
-7
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
5
5
5
Shares Outstanding
1,084
1,101
1,113
Market Capitalization
93
120
113

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2
3
4
Cash, Cash Equivalents & STI
2
3
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
10
11
11
Payables & Accruals
9
9
9
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.24%
10.01%
-1.85%
Free Cash Flow
35.78%
12.36%
-2.66%
Net Income, GAAP
19.71%
1.45%
6.6%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) develops and commercializes protein-based fibers, including recombinant spider silk and high-performance polymers, using recombinant DNA technology and genetically engineered domesticated mulberry silkworms; its core proprietary technologies encompass natural and engineered spider silk variants such as BAM-1 hybrid, BAM-1 Alpha, and advanced Generation III platforms employing non-CRISPR gene editing with large plasmid knock-in knock-out methods for producing nearly pure spider silk customized for strength, flexibility, and other properties; products target performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics, ballistic protection for military and police, geotextiles, protective clothing, transportation and building textiles, and functional sportive textiles. The company, founded in 2006 and headquartered in Ann Arbor, Michigan, operates primarily in the United States with production facilities including two rearing centers in a leading global silk production region managed through its wholly owned subsidiary Prodigy Silk, alongside the Prodigy Textile brand as a DBA. Recent developments include securing a $10 million standby equity purchase agreement with YA II PN (Yorkville) in January 2025 to fund production expansion, inventory buildup, consumer product development, and sales partnerships over 36 months; achieving record spider silk output in a single early 2025 production run surpassing all of 2024's combined production; launching a second parallel production facility, a diapausing silkworm system, and three new spider silk strains including replacements for BAM-1 lines to enhance yield and premium quality for high-end textile markets; accelerating operations into two purpose-built commercial rearing centers by August 2025 with equipment transfers from the original pilot facility; initiating a sixth 2025 production cycle in October featuring large-scale BAM-1 Alpha deployment; pursuing an additional rearing center; nearing a three-year government collaboration for hybridized silkworm scaling; and launching a significant hiring initiative in November 2025 to support next-generation technology expansion.

Company News

  • Kraig Labs Advances Commercial Spider Silk Production with New Customer Shipments and New Silkworm Research

  • Kraig Labs Advances Commercial Spider Silk Production with New Customer Shipments and New Silkworm Research

  • Kraig Biocraft Laboratories Takes Spider Silk Optimization Beyond Genetics with New Dietary Additive Program

  • Why Kraig Labs' Spider Silk Could Have a Future in Aerospace

  • Kraig Labs Moves Beyond Bold Breakthrough

  • Kraig Biocraft Laboratories Launches Performance Yarn Development Program and Ships Spider Silk to Yarn and Aerospace Innovator

  • Kraig Biocraft Laboratories Selected to Present to the International Sericultural Commission Congress on the Impact of Bioengineering on Commercial Silk Markets

  • What's More Space Age Than Spider Silk Spun by Kraig Labs' Transgenic Silkworms?

  • Indistinguishable From Magic: How Kraig Labs Brought Spider Silk into Reality

  • Kraig Biocraft Laboratories Ramps Full Production Across All Three Production Centers as Commercial Deliveries Begin to Take Hold

  • Kraig Labs Takes Biggest Step Yet and Ships First Commercial Spider Silk Order, as Performance Brand Set to Put Breakthrough Fiber to the Test

  • Kraig Labs Opens the Global Market for Its Spider Silk with Historic Multi-Kilogram Order

  • Kraig Biocraft Laboratories Ships its First Commercial Spider Silk Yarn Order for Performance Sports Brand

  • Kraig Labs' Atlas Milestone Opens the Door to Potential Historic Spider Silk Advancements

  • Kraig Biocraft Laboratories Reaches Major Scientific Milestone with Completion of Functional and Living Atlas Gene Library

  • As New York Fashion Week Kicks Off, Kraig Labs Advances Spider Silk for Fashion's Next Generation of Designers

  • Kraig Biocraft Laboratories Highlighted by Tech Times for Advancing Spider Silk from Science Fiction Toward Commercial Reality

  • Kraig Biocraft Laboratories Boosts Spider Silk Output More Than 30% During the Most Technically Challenging Season of the Year

  • Kraig Biocraft Laboratories CEO Kim Thompson Publishes Thought Leadership Article on the Next Chapter of Authored Biology in Biocompare

  • Kraig Biocraft Laboratories CEO Kim Thompson Featured in Just Style, a Leading Global Apparel Industry Trade Publication